Education
About Us
Working with TipRanks
Follow Us
Eikon Therapeutics, Inc. (EIKN)
NASDAQ:EIKN
EIKN Stock Chart & Stats
$13.18
--
Market closed
$13.18
--
Day’s Range― - ―
52-Week Range$12.62 - $17.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-2.26
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,100,143
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$25.60Price Target Upside94.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Eikon Therapeutics, Inc. News
EIKN FAQ
What was Eikon Therapeutics, Inc.’s price range in the past 12 months?
Eikon Therapeutics, Inc. lowest stock price was $12.62 and its highest was $17.40 in the past 12 months.
What is Eikon Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Eikon Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Eikon Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Eikon Therapeutics, Inc. overvalued?
According to Wall Street analysts Eikon Therapeutics, Inc.’s price is currently Undervalued.
Does Eikon Therapeutics, Inc. pay dividends?
Eikon Therapeutics, Inc. does not currently pay dividends.
What is Eikon Therapeutics, Inc.’s EPS estimate?
Eikon Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eikon Therapeutics, Inc. have?
Eikon Therapeutics, Inc. has 54,100,143 shares outstanding.
What happened to Eikon Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eikon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in EIKN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of protein interactions in living cells. Its products includes EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004 are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004, to address brain metastases and primary brain malignancies; EIK1005 a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006. The company was incorporated in 2019 and is based in Millbrae, California.
EIKN Stock 12 Month Forecast
Average Price Target
$25.60
▲(94.23% Upside)